PEARRL is a European Training Network (ETN) funded under the Horizon 2020 Marie Sklodowska-Curie actions. It brings together European Pharma industry, academia and regulatory agency partners in a multisectorial team to deliver a unique research and training programme for 15 Early Stage Researchers (ESR).
The European Pharma industry is a major contributor to EU well-being, both in public health and economic terms. To maintain global leadership, it must respond to challenges from low-cost producers by bringing new drug molecules to market in a streamlined, cost-effective manner. This strategy is emphasized by initiatives of European regulators to quicken the approval of breakthrough drugs so patients can gain faster access to life-saving drugs.
The main research objectives of the PEARRL research programme are to deliver novel bio-enabling formulations and new biopharmaceutics tools to predict their in vivo performance as a means to improve efficiency and cost-competitiveness in drug development, thus facilitating earlier access of patients to “breakthrough therapies”.
PEARRL will train 15 Early Stage Researchers (ESR) who can develop such new bio-enabling formulations (“better drugs”), biorelevant and in silico methods to predict formulation performance in vivo (“streamlined development”) and serve as communication bridgers between research and regulatory science (“accelerated approval”), thus bringing Pharma and regulatory objectives to fruition.
"Applying for EU grants should carry a ‘PG’ warning…don’t try this unsupervised! accelopment provided the expertise, guidance and know-how to make the difference between a good idea for research funding and a successfully funded research grant."
Dr Brendan Griffin, University College Cork, IE